Ophthalmology Times - Ophthalmic NewsThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. Subscribe to this data using MyMedWorm.Subscribe to this data using GoogleReader.Subscribe to this data using Bloglines.Subscribe to this data using MyYahoo.

Get the very latest Swine Flu news via the MedWorm Swine Flu RSS news feed - updated hourly from thousands of authoritative health and news sources.

• Contents
• Discussions

Pages: 1  2  3  4  5  6  7  8  

Inspire initiates phase II trials with azithromycin for treatment of blepharitisEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Inspire Pharmaceuticals Inc. announced it has initiated two phase II clinical trials with azithromycin ophthalmic solution 1% (AzaSite) to pursue a potential indication for the treatment of blepharitis. The drug currently is approved by the FDA for the treatment of bacterial conjunctivitis. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - May 7, 2009 Category: Opthalmology Source Type: journals

Second Sight doubles patient enrollment for retinal implant studyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Second Sight Medical Products Inc. announced that the FDA has granted approval for up to 20 people who are blind or who have severely impaired vision due to retinitis pigmentosa to participate in a feasibility study for its retinal implant (Argus II Retinal Implant) in the United States. Ten RP volunteers are participating in the U.S. study and an additional 12 RP volunteers are participating in similar studies throughout Europe and Mexico. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - May 6, 2009 Category: Opthalmology Source Type: journals

Novagali Pharma IND cleared for phase III study of cationic emulsion of latanoprostEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Novagali Pharma announced that the company's investigational new drug application to conduct a phase III clinical trial of Nova21027 (Catioprost), a cationic emulsion of latanoprost for the treatment of glaucoma, has been granted by the FDA. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - May 6, 2009 Category: Opthalmology Source Type: journals

Wilmer Eye Institute breaks ground on new, upgraded facilityEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Wilmer Eye Institute of Johns Hopkins University School of Med-icine opened a $100 million, privately funded, 207,000-square-foot facility that will build on the current research and clinical space for its 130 full-time faculty (90 clinician scientists; 40 PhD researchers). (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - October 11, 2007 Category: Opthalmology Source Type: journals

Photochromic IOL to be available in EuropeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
S (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - July 20, 2007 Category: Opthalmology Source Type: journals

FDA OKs azithromycin 1% ophthalmic solutionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
S (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - July 7, 2007 Category: Opthalmology Source Type: journals

Bepotastine promising against ocular itchingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
S (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 28, 2007 Category: Opthalmology Source Type: journals

Bausch & Lomb to merge with private equity firmEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
S (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 27, 2007 Category: Opthalmology Source Type: journals

ASCRS launches ectasia registryEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
S (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 26, 2007 Category: Opthalmology Source Type: journals

Texas centers ready to help restore sightEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Boca Raton, FL—Nova Vision Inc. has installed its device (Vision Restoration Therapy [VRT]) in two centers in Texas, where therapists can help restore sight to people who have been left partially blind by a stroke or brain injury. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 22, 2007 Category: Opthalmology Source Type: journals

Dr. Campbell joins Sophrona advisory boardEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Minneapolis—Robert C. Campbell, MD, has joined the advisory board of Sophrona Solutions. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 21, 2007 Category: Opthalmology Source Type: journals

The price of visionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Chicago?The aggregate cost related to adult vision conditions in the United States has climbed to an estimated $51.4 billion, according to a pioneering report from Prevent Blindness America (PBA). (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 14, 2007 Category: Opthalmology Source Type: journals

Cyclosporine A tested for dry eyeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Tampa, FL?Two companies are researching cyclosporine A as a potential treatment for dry eye syndrome. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 14, 2007 Category: Opthalmology Source Type: journals

Trials begin on drop to heal ocular woundsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bethesda, MD?The FDA will allow Regene-Rx Biopharmaceuticals Inc. to begin a phase II trial of its Thymosin beta 4 (TB4) for the treatment of diabetic patients undergoing vitrectomy surgery. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 14, 2007 Category: Opthalmology Source Type: journals

AMO recalls lens solutionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
In response to reports received from the Centers for Disease Control and Prevention (CDC) regarding eye infections from Acanthamoeba, Advanced Medical Optics (AMO) has voluntarily recalled its Complete MoisturePlus contact lens solutions. No evidence suggests that the voluntary recall is related to a product contamination issue, according to AMO. The company is working with the CDC, FDA, and others to ensure that consumers are aware of the need for proper contact lens disinfection and proper lens handling. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 14, 2007 Category: Opthalmology Source Type: journals

Spreading agent introduced to marketEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
San Diego?Baxter Healthcare Corp. has launched its hyaluronidase human injection (Hylenex recombinant) for use in enhancing the absorption and dispersion of injected ophthalmic anesthetics. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 14, 2007 Category: Opthalmology Source Type: journals

Photochromic IOL to be available in EuropeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Irvine, CA?Medennium Inc. expects that its photochromic IOL (Aurium) will be available in all European countries by September now that it has obtained CE mark clearance to market the lens. It is the first and only photochromic IOL, according to the company. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 14, 2007 Category: Opthalmology Source Type: journals

Therapy improves visual field defectEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Boston--More than 70% of stroke and traumatic brain injury (TBI) survivors with homonymous visual-field defects demonstrated a visual field improvement of more than 3% following a six-module course of vision restoration therapy, according to a study released by NovaVision. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 14, 2007 Category: Opthalmology Source Type: journals

AMO phaco system offers dual-pump fluidicsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
San Diego?Advanced Medical Optics (AMO) Inc. has introduced a new phacoemulsification system featuring dual-pump fluidics (WhiteStar Signature with Fusion). (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 14, 2007 Category: Opthalmology Source Type: journals

Trials to test efficacy of ocular implantsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Lincoln, RI?Biotechnology firm Neurotech Pharmaceuticals Inc. has begun two phase II/III clinical trials with NT-501, the company's lead Encapsulated Cell Technology (ECT) product for the treatment of visual loss associated with retinitis pigmentosa. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 14, 2007 Category: Opthalmology Source Type: journals

Six researchers win $100,000 grantsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Fort Worth, TX—The Alcon Research Institute (ARI) has given six ocular researchers $100,000 each to further their research endeavors. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - June 14, 2007 Category: Opthalmology Source Type: journals

Bepotastine promising against ocular itchingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Preliminary phase II/III results of a clinical trial of bepotastine for the treatment of allergic conjunctivitis show statistically significant results against some symptoms, according to ISTA Pharmaceuticals Inc. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - May 31, 2007 Category: Opthalmology Source Type: journals

ASCRS launches ectasia registryEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The American Society of Cataract and Refractive Surgery (ASCRS) has launched the ASCRS International Ectasia Registry as part of a two-phase project to define ectasia more precisely, determine its frequency, and identify risk factors. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - May 31, 2007 Category: Opthalmology Source Type: journals

FDA OKs azithromycin 1% ophthalmic solutionEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
InSite Vision Inc. expects its azithromycin 1% ophthalmic solution (Aza- Site) to be launched commercially in the United States in the second half of this year now that the FDA has approved the company's new drug application. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - May 31, 2007 Category: Opthalmology Source Type: journals

Bausch & Lomb to merge with private equity firmEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
After more than 150 years in business (69 of them as a public company), Bausch & Lomb has accepted an offer to merge with Warburg Pincus, a private equity firm. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - May 31, 2007 Category: Opthalmology Source Type: journals

Horizontal tightening of upper eyelid helps with floppy eyelid syndromeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Horizontal eyelid tightening alone results in secondary improvement in the ptosis associated with floppy eyelid syndrome, according to the results of a case series in 24 eyelids of 18 patients. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - May 14, 2007 Category: Opthalmology Source Type: journals

Robert Osher, MD, treasures his Charles Kelman Award presented by Hellenic SocietyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Robert H. Osher, MD, has received numerous accolades over his lifetime as an innovative surgeon, video producer, athletic coach, professor, and medical director of a large practice. But, he said, the Charles Kelman Award he received recently from the Hellenic Society of Intraocular Implant & Refractive Surgery is among his most treasured. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 30, 2007 Category: Opthalmology Source Type: journals

$4.75 million grant to fund stem-cell workEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Lincy Foundation has given the first installment of a 4-year, $4.75 million grant to the Oregon Retinal Degeneration Center at Oregon Health & Science (OHSU) Casey Eye Institute. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 30, 2007 Category: Opthalmology Source Type: journals

Phase II trial to study DMEEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
The Juvenile Diabetes Research Foundation (JDRF) is enrolling patients in a study to test the long-term safety and effectiveness of intraocular injections of ranibizumab (Lucentis, Genentech) in patients with diabetic macular edema (DME) (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 30, 2007 Category: Opthalmology Source Type: journals

Accommodating IOL leads revenue surgeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Aliso Viejo, CA—First-quarter 2007 revenues for eyeonics inc., the developer of the crystalens accommodating IOL, have increased 36% over the same period last year, the company said. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 30, 2007 Category: Opthalmology Source Type: journals

CDC examines apparent Acanthamoeba keratitis outbreakEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ophthalmologists and epidemiologists around the country are growing concerned about an apparent increase in the number of Acanthamoeba keratitis cases they are seeing. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 30, 2007 Category: Opthalmology Source Type: journals

Protective eye gear essential for modern soldierEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Preventing ocular injuries during war by using protective devices may reduce the incidence of these injuries, which currently hold the number four slot for highest incidence after amputation, traumatic brain injury, and post-traumatic stress disorder. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 30, 2007 Category: Opthalmology Source Type: journals

Iridex settles with SynergeticsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
S (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 30, 2007 Category: Opthalmology Source Type: journals

State policies reviewed at first 'Vision Summit'Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Vision health advocates convened here to review data and the effectiveness of various state policy models to provide children's vision care in what is touted as the first "Vision Summit." (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 30, 2007 Category: Opthalmology Source Type: journals

Generic drug sale blocked until 2009Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
A federal appellate court has blocked the largest Canadian-owned pharmaceutical company from manufacturing and selling a generic version of Allergan's ketorolac tromethamine ophthalmic solution 0.5% (Acular). (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 30, 2007 Category: Opthalmology Source Type: journals

NicOx, Pfizer announce phase II trial of latanoprost derivativeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NicOx and Pfizer will initiate a phase II, dose-finding study of its PF-03187207 compound for the treatment of patients with glaucoma and ocular hypertension. The 28-day trial is designed to compare the safety and efficacy of the drug with that of latanoprost (Xalatan, Pfizer Ophthalmics). (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

Ophthonix picks Osbaldeston as chief executive officerEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ophthonix has named Stephen J. Osbaldeston as its chief executive officer. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

Anti-VEGF peptide near phase I clinical trialsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Potentia Pharmaceuticals said it would initiate phase I clinical trials to evaluate its drug POT-4, for the treatment of age-related macular degeneration (AMD). (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

Topigen Pharmaceuticals, Novagali Pharma to collaborate on drug-delivery systemEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Topigen Pharmaceuticals and Novagali Pharma will collaborate on products designed to improve the bioadhesion and efficacy of RNA-targeting therapeutics delivered to the nasal membrane and ocular surface. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

Newly formed Opko Corp. plans to study wet AMD therapyEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Newly formed Opko Corp. plans a phase III trial of bevasiranib (formerly Cand5) as maintenance therapy for wet AMD in combination with ranibizumab (Lucentis, Genentech). (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

Bausch & Lomb earns NTIOL status for two lens productsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Bausch & Lomb has earned NTIOL status for its SofPort Advanced Optics and SofPort Advanced Optics with Violet Shield lenses. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

Ostrov joins NuLens board of directorsEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
NuLens has named Gerald M. Ostrov to its board of directors. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

Ophthalmology Times wins two 2007 Neal Awards for editorial excellenceEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Ophthalmology Times magazine earned two awards in the 53rd annual Jesse H. Neal National Business Journalism Awards competition recognizing editorial excellence. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

Iridex, Synergetics square off to settle patent disputeEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Iridex Corp. and Synergetics USA Inc. are headed to trial to settle a patent dispute. Iridex claims that Synergetics relied on its patented technology to create a connector for handheld probes it sold between 1999 and mid-2006. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

Dr. Osher to sign copies of his books for children at ASCRS meetingEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Robert H. Osher, MD, carves time out of his professional, academic, and personal responsibilities to write books for children. He will sign copies of seven of his titles during the American Society of Cataract and Refractive Surgery (ASCRS) annual meeting. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

Dr. Singh appointed editor of British Journal of Ophthalmology (USA)Email this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Arun D. Singh, MD, has been named editor of the British Journal of Ophthalmology (USA). (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

Carl Zeiss Vision announces Howard as new presidentEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Frederick Howard has been named the new president and general manager, Americas, for Carl Zeiss Vision. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals

VEGF drug improves vision in patients with wet AMDEmail this article to a colleague. Save this article to My Clippings. Discuss or comment on this article.
Based on a planned, interim analysis of a phase II randomized study, Regeneron Pharmaceuticals and Bayer HealthCare said patients with wet age-related macular degeneration (AMD) who received just one dose of their vascular endothelial growth factor (VEGF) drug (Trap-Eye) maintained or improved vision at 12 weeks. (Source: Ophthalmology Times - Ophthalmic News)
Source: Ophthalmology Times - Ophthalmic News - April 14, 2007 Category: Opthalmology Source Type: journals